期刊文献+

人呼吸道合胞病毒裂解条件的初步探索 被引量:1

Preliminary Study on Condition for Lysis of Human Respiratory Syncytial Virus
原文传递
导出
摘要 目的对人呼吸道合胞病毒(HRSV)的裂解条件进行初步探索,为研制HRSV裂解纯化疫苗奠定基础。方法用不同的裂解剂,以不同浓度和温度对HRSV裂解不同时间,以HRSV的F及G蛋白为目标蛋白,对得到的蛋白进行还原蛋白电泳分析及Western blot鉴定,电镜观察验证裂解效果。结果1%浓度的TritonX-100在4℃作用90min,对HRSV的裂解效果优于其他裂解剂。电镜观察可见病毒样品呈云絮状裂解;Western blot分析表明,特异性条带为HRSV的F蛋白。结论已初步筛选出HRSV的裂解条件,其对HRSV的裂解效果较好。 Objective To explore the condition for lysis of human respiratory syncytial virus (HRSV) and lay a foundation of preparing purified HRSV cleavage vaccine. Methods HSRV was lysed with various lytic agents at various concentrations and temperatures for various time, then identified by reduced electrophoresis and Western blot and observed by electron microscopy. Results After lysis with 1% Triton X-100 at 4℃ for 90 rain, HRSV were nebular particles under electron microscope, and specific F protein band was proved by Western blot. Conclusion The condition for lysis of HRSV was preliminarily screened.
出处 《中国生物制品学杂志》 CAS CSCD 2009年第5期501-504,共4页 Chinese Journal of Biologicals
关键词 人呼吸道合胞病毒 裂解条件 亚单位疫苗 Human respiratory syncytial virus (HRSV) Lysis condition Subunit vaccine
  • 相关文献

参考文献9

  • 1Crowe JE Jr. Current approaches to the development of vaccines against disease caused by respiratory syncytial virus (RSV) and parainfluenza virus (PIV). A meeting report of the WHO Programme for Vaccine Development. Vaccine, 1995,13 (4): 415-421.
  • 2芦起,谢正德,申昆玲.呼吸道合胞病毒的蛋白特征及抗原变异[J].国外医学(病毒学分册),2005,12(3):76-80. 被引量:2
  • 3Sakurai H, Williamson RA, Crowe JE, et al. Human antibody responses to mature and immature forms of viral envelope in respiratory syncytial virus infection: significance for subunit vaccines. J Virol, 1999, 73 (4): 2956-2962.
  • 4詹曦菁,秦晓勇,刘丽英,孔健.麻疹病毒的纯化及其在麻疹IgG EIA诊断试剂中的应用[J].中国卫生检验杂志,2007,17(4):618-621. 被引量:3
  • 5俞建昆 谢忠平 董承红 等.PEG沉淀HAV的最佳条件.中国生物制品学杂志,1997,10(1):52-52.
  • 6Tristram DA, Welliver RC, Hogerman DA, ct al. Second-year surveillance of recipients of a respiratory syncytial virus (RSV) F protein subunit vaccine, PFP-1: evaluation of antibody sistence and possible disease enhancement. Vaccine, 1994, 12 (6): 551-556.
  • 7Falsey AR, Walsh EE. Safety and immunogenicity of respiratory syncytial virus subunit vaccine (PFP-2) in ambulatory adult over age 60. Vaccine, 1996, 14( 13 ): 1214-1218.
  • 8Klinguer-Hamour C, Libon C, Plotnicky-Gilquin H, et al. DDA adjuvant induces a mixed Th1/Th2 immune response when associated with BBG2Na, a respiratory syncytial virus potential vaccine. Vaccine, 2002, 20 (21-22): 2743-2751.
  • 9王济源.呼吸道合胞病毒疫苗开发策略[J].国外医学(预防.诊断.治疗用生物制品分册),2004,27(1):7-10. 被引量:2

二级参考文献37

  • 1张晋琳,王保生,许晓国,张伟,孙晖,邵荣标.血凝抑制试验与酶联免疫吸附试验检测麻疹抗体两方法的比较[J].疾病监测,2004,19(12):472-473. 被引量:3
  • 2Jordan Report,2002:165-168.
  • 3Schmidt AC et al. J Virol,2002,76: 1089-1099.
  • 4Klinguer C et al. Vaccine,2001,19:4236-4244.
  • 5Sullender WM. Respiratory syncytial virus genetic and antigenic diversity. Clin Microbiol Rev 2000,13:1-15.
  • 6Melero JA, Garcia-Barreno B, Martinez I, Pringle CR, Cane PA.Antigenic structure, evolution and immunobiology of human respiratory syncytial virus attachment (G) protein. J Gen Virol. 1997,78:2411-2418.
  • 7WAYNE M. SULLENDER Respiratory syncytial virus Genetic and Antigenic diversity. J Clin microbial Rev
  • 8Chang J, Srikiakhachorn A and Braciale TJ. Visualization and characterization of respiratory syncytial virus F-specific CD8 + T cells during experimental virus infection. J Immunol, 2001, 167:4254.
  • 9Leitner WW, Ying H and Restifo NP. DNA and RNA-based vaccines: principles, progress and prospects. Vaccine, 1999, 18:765.
  • 10Nilsson C, Makitalo B, Berglund P et al. Enhanced simian immunodeficiency virus-specific immune responses in macaques induced by priming with recombinant Semliki Forest virus and boosting with modified vaccinia virus Ankara. Vaccine, 2001, 19: 3526.

共引文献7

同被引文献4

  • 1王善辉,余兵兵,王希良,李培锋.呼吸道合胞病毒融合蛋白F在重组杆状病毒表达系统中的表达及抗原性研究[J].免疫学杂志,2009,25(3):267-270. 被引量:2
  • 2Polack FP,Karron RA.The future of respiratory syncytial virus vaccine development.Pediatr Infect Dis J,2004,23(Suppl):65-73.
  • 3Roux X,Dubuquoy C,Durand G,et al.Sub-nucleocapsid nanoparticles:a nasal vaccine against respiratory syncytial virus.P Lo S ONE,2008,3:1766-1769.
  • 4Gill MA,Palucka KA,Barton T,et al.Mobilization of plasmacytoid and myeloid dendritic cells to mucosa sites in children with respiratory syncytial virus and other viral respiratory infections.J Infect Dis,2005,291:1105-1115.

引证文献1

二级引证文献8

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部